Liver Cancer Study
A study exploring a potential new combination treatment in people who are diagnosed with hepatocellular carcinoma and the cancer has spread to other tissues or organs or has progressed after locoregional treatment.
Now Enrolling
Trial ID: NCT06679985
About This Study
CADILYZE™ 202
Liver Cancer Study
Clinical Trial ID: NCT06679985
CADILYZE™ 202 is a clinical study that is designed to test whether a combination of three drugs – a new research drug called casdozokitug (CHS-388), toripalimab, and bevacizumab – may work against liver cancer. This combination is investigational and not approved for any disease.
Who Can Participate?
Is this trial right for you?
You may be eligible for the CADILYZE™ 202 clinical trial if:
You have liver cancer
You cannot undergo surgery for liver cancer
Your cancer has spread to tissues near the liver (locally advanced disease) or to other organs (metastatic disease)
Your cancer has progressed after locoregional (localized to the liver and surrounding lymph nodes) treatment
Only the study team can determine if you meet all eligibility criteria. For more information on eligibility criteria, please visit https://clinicaltrials.gov/study/NCT06679985#participation-criteria or contact one of the study sites. Your doctor may also be able to help you.
Frequently Asked Questions
Answers to Some Questions You May Have for the CADILYZE™ 202 Clinical Trial
What is informed consent?
An Informed Consent Form helps you understand all the facts about your treatment.
What is this study about?
CADILYZE™ 202 is a clinical study that is designed to test whether a combination treatment of 3 drugs – a new research drug called casdozokitug (CHS-388), toripalimab, and bevacizumab – may work against liver cancer.
What is casdozokitug (CHS-388)?
Casdozokitug (CHS-388) is a type of drug called immunotherapy. It is an investigational drug not yet approved by the FDA.
What are toripalimab and bevacizumab?
Toripalimab is an immunotherapy. It is FDA approved for treating another cancer but not liver cancer. Bevacizumab is a drug that prevents the formation of new blood vessels in the tumor (anti-angiogenesis.) Bevacizumab is FDA approved for treating liver cancer in combination with a different drug.
How do I sign up for the study?
First, talk to your doctor to see if this study may be right for you. You can also learn more about clinical trials by visiting a website like ClinicalTrials.gov or click here to find locations near you where the study is ongoing. Each study location has a website or phone number where you can ask questions. A nurse or study leader will help you understand what’s needed to join.
How long will I be in this study?
The treatment may be for up to 24 months, with follow-up visits for another 24 months or more.
Are there any disadvantages to taking part in this study?
The disadvantages of taking part in this study are those associated with treatment such as side effects and follow up as well as the time and inconvenience to you of attending the research site for further visits.
Will I have to pay for anything?
You will not need to pay for any of the drugs in the study, medical visits, laboratory tests, or any imaging and procedures that may be done as part of the study.
What to Expect
Guiding You Through Each Step with Care
If you qualify and choose to participate in our CADILYZE™ 202 clinical trial, here’s what the process typically involves:
1
Screening
After you sign an Informed Consent Form, the study team will evaluate you to confirm that you can participate in the study.
2
Treatment
You will be randomly assigned to one of the three arms and begin to receive treatment.
3
Follow-Up
Your health and disease status will be monitored during treatment and for a few years following treatment.
CADILYZE™ 202 Trial Sites
Finding a location that works for you
Patient Support
Patient Advocacy Organizations
